<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To examine the potential of the two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) inhibitors infliximab and etanercept as remission-inducing agents in <z:hpo ids='HP_0011010'>chronic</z:hpo> therapy-resistant <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorders</z:e> of immune or non-immune pathogenesis </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: 14 patients with <z:e sem="disease" ids="C0085253" disease_type="Disease or Syndrome" abbrv="">adult Still's disease</z:e>/<z:e sem="disease" ids="C1096155" disease_type="Disease or Syndrome" abbrv="">macrophage activation syndrome</z:e> (4), Wegener's disease (3), <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease (3), keratoscleritis (1), lymphomatous tracheo-<z:e sem="disease" ids="C0006277" disease_type="Disease or Syndrome" abbrv="">bronchitis</z:e> (1) <z:e sem="disease" ids="C0271270" disease_type="Disease or Syndrome" abbrv="">Cogan's syndrome</z:e> (1), and rapidly destructive crystal <z:hpo ids='HP_0003040'>arthropathy</z:hpo> (1) were treated with infliximab (n = 10) and etanercept (n = 4) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients showed organ-threatening progression of their diseases with resistance to conventional immunosuppressive medication </plain></SENT>
<SENT sid="3" pm="."><plain>Therapeutic benefit was assessed clinically and by documenting organ-specific functional and morphological alterations </plain></SENT>
<SENT sid="4" pm="."><plain>Side effects were compared with the data of our clinic's <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) patients treated by TNF inhibitors </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A rapid and dramatic beneficial effect was documented in 9 patients and a moderate one in 5 </plain></SENT>
<SENT sid="6" pm="."><plain>Best responses (clinical and laboratory parameters) were seen in patients with <z:e sem="disease" ids="C1096155" disease_type="Disease or Syndrome" abbrv="">macrophage activation syndrome</z:e>/<z:e sem="disease" ids="C0085253" disease_type="Disease or Syndrome" abbrv="">adult Still's disease</z:e> and <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, while the results were less impressive in those with Wegener's disease, <z:e sem="disease" ids="C0271270" disease_type="Disease or Syndrome" abbrv="">Cogan's syndrome</z:e>, idiopathic cerato-<z:hpo ids='HP_0100532'>scleritis</z:hpo> and lymphomatous <z:e sem="disease" ids="C0040586" disease_type="Disease or Syndrome" abbrv="">tracheobronchitis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> cases <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> and systemic <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> could be reduced or discontinued </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: TNF inhibition may be highly effective in patients with severe, therapy-resistant <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorders</z:e> </plain></SENT>
</text></document>